Denali Therapeutics (DNLI) Receivables - Net (2018 - 2025)
Denali Therapeutics (DNLI) has disclosed Receivables - Net for 7 consecutive years, with $1.6 million as the latest value for Q4 2025.
- Quarterly Receivables - Net fell 26.3% to $1.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.6 million through Dec 2025, down 26.3% year-over-year, with the annual reading at $1.6 million for FY2025, 26.3% down from the prior year.
- Receivables - Net for Q4 2025 was $1.6 million at Denali Therapeutics, down from $1.9 million in the prior quarter.
- The five-year high for Receivables - Net was $15.2 million in Q2 2021, with the low at $1.4 million in Q2 2024.
- Average Receivables - Net over 4 years is $3.1 million, with a median of $1.9 million recorded in 2024.
- The sharpest move saw Receivables - Net skyrocketed 4972.67% in 2021, then plummeted 58.82% in 2024.
- Over 4 years, Receivables - Net stood at $15.2 million in 2021, then tumbled by 82.26% to $2.7 million in 2023, then decreased by 19.59% to $2.2 million in 2024, then fell by 26.3% to $1.6 million in 2025.
- According to Business Quant data, Receivables - Net over the past three periods came in at $1.6 million, $1.9 million, and $1.4 million for Q4 2025, Q3 2025, and Q2 2025 respectively.